PEAK BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0086 USD | 0.00% |
|
+1.18% | -95.41% |
| Mar. 05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
| Feb. 16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2021 | 0.53 | Sales 2022 | 0.61 | Capitalization | 84.05M |
|---|---|---|---|---|---|
| Net income 2021 | -8M | Net income 2022 | -13M | EV / Sales 2021 | - |
| Net Debt 2021 | 1.29M | Net Debt 2022 | 7.83M | EV / Sales 2022 | 151,191,556 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-5.67
x | Employees | 21 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 60.94% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +1.18% | ||
| Current month | +1.18% | ||
| 1 month | +65.38% | ||
| 3 months | -77.19% | ||
| 6 months | -89.24% | ||
| Current year | -95.41% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.000.26
1 year
0.001.00
3 years
0.0015.00
5 years
0.0015.00
10 years
0.0015.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen LaMond
CEO | Chief Executive Officer | - | 22-10-31 |
| Director of Finance/CFO | 62 | 22-10-31 | |
Satyajit Mitra
BRD | Director/Board Member | 50 | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Neal
BRD | Director/Board Member | 68 | 22-10-31 |
Ho Young Huh
CHM | Chairman | 54 | 22-10-31 |
Michael Friedman
BRD | Director/Board Member | - | 23-08-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 0.0086 | 0.00% | 1,422 |
| 24-05-07 | 0.0086 | +1.18% | 240 |
Delayed Quote OTC Markets, May 09, 2024 at 02:27 pm EDT
More quotes
Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Companyâs lead product candidate, PHP-303, is a small molecule, fifth generation, phase II clinical-ready neutrophil elastase (NE) inhibitor (NEI). PHP-303 is an oral, once daily, 0.65 nanomolar, selective, small molecule reversible inhibitor of NE designed to inhibit its bioactive form that the Company is developing for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder that may result in lung disease or liver disease and, potentially, acute respiratory distress syndrome (ARDS). The Companyâs advanced platform in oncology utilizes its toxin, PH-1 or Thailanstatin, to generate a pipeline of antibody-drug-conjugates (ADC) product candidates that are differentiated from traditional ADC-based therapies.
| 1st Jan change | Capi. | |
|---|---|---|
| -95.41% | 195K | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- PKBO Stock